The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Teligent Announces FDA Approval of Desonide Ointment
Mar. 14, 2019 08:58AM PST
Pharmaceutical InvestingTeligent (NASDAQ:TLGT) has announced it has received approval from the FDA for its abbreviated new drug application (ANDA) of desonide ointment, 0.05 percent. As quoted in the press release: is is Teligent’s second approval of 2019, and its thirty-fourth approval from its internally-developed pipeline of topical generic pharmaceutical medicines. Based on recent IQVIA data from …
Teligent (NASDAQ:TLGT) has announced it has received approval from the FDA for its abbreviated new drug application (ANDA) of desonide ointment, 0.05 percent.
As quoted in the press release:
is is Teligent’s second approval of 2019, and its thirty-fourth approval from its internally-developed pipeline of topical generic pharmaceutical medicines.
Based on recent IQVIA data from January 2019, the total addressable market for this product is approximately $12.5 million.
“This first-review-cycle approval again shows the strength of Teligent’s internal R&D capabilities as we continue to build our portfolio and realize the value of our pipeline,’’ commented Jason Grenfell-Gardner, President and CEO of the Company.
Mr. Grenfell-Gardner continued, “We now have thirty-nine topical generic pharmaceutical products in the US portfolio, in addition to our four US injectable products.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.